Recent Developments in Nuclear Medicine in the Management of Bone Metastases
Authors:
- S PackianathanSPS Packianathan
- Philip S. BoernerPBPhilip S. Boerner
- Ashesh B. JaniAJAshesh B. Jani
- Srinivasan VijayakumarSVSrinivasan Vijayakumar
- Vani VijayakumarVVVani Vijayakumar
- 1 October 2005
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 28 (5) , 513-520
Abstract
To review recent developments and to examine the role of nuclear medicine-based radionuclide therapy in the management of bone metastases. Recent developments in the use of radionuclides were broadly reviewed in the context of treatment paradigms, radionuclide toxicity, cost, and overall outcomes, and an impression of the use of radionuclides in metastatic bone disease was derived. Through a number of studies, radionuclide therapy has been shown to be an efficacious and cost-effective means of alleviating bone pain in metastatic disease. Moreover, its early use in pain therapy may limit cancer progression by inhibiting oligometastases. Thus, radionuclides can significantly decrease patient morbidity, increase patient survival, and perhaps attenuate the aggressiveness of cancer. Nonetheless, in comparison with analgesics, external beam radiotherapy, or surgery, it still appears to have lower priority among medical oncologists. Bone pain palliation is critical for cancer patients afflicted with bone metastases, but radionuclides remain underutilized in such treatments. The authors propose that physician education regarding radionuclide therapy be improved and additional investigations to evaluate newer radionuclides and treatment paradigms (eg, higher activities, repetitive or cyclic administration, chemosensitization, or chemosupplementation) be strongly encouraged. A comprehensive and an interdisciplinary clinical approach toward increasing the use of radionuclides in alleviating metastatic bone pain is proposed. Data from clinical collaborations will help optimize radiopharmaceutical therapy for pain palliation, increase its awareness among oncologists, and contribute effectively to patient palliation and quality-of-life improvements.Keywords
This publication has 50 references indexed in Scilit:
- Pain management in cancer patients with bone metastases remains a challengeJournal of Pain and Symptom Management, 2004
- Rhenium-188-HEDP Therapy for the Palliation of Pain Due to Osseous Metastases in Lung Cancer PatientsCancer Biotherapy and Radiopharmaceuticals, 2003
- High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone MetastasesJournal of Clinical Oncology, 2002
- A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Effective and economical option for pain palliation in prostate cancer with skeletal metastasesNuclear Medicine Communications, 1999
- Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in ChinaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.Journal of Clinical Oncology, 1998
- Schmerztherapie mit Rhenium-186 HEDP bei multiplen KnochenmetastasenNuklearmedizin-Nuclear Medicine, 1996
- Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastasesSeminars in Nuclear Medicine, 1992